ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
Asterias Biotherapeutics Common Series A

Asterias Biotherapeutics Common Series A (AST)

0.945
0.00
(0.00%)
마감 18 1월 6:00AM
0.00
0.00
(0.00%)
시간외 거래: -

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
0.945
매수가
-
매도가
-
거래량
0.00
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
전일 종가
0.945
개장가
-
최근 거래 시간
마지막 거래 시간
평균 볼륨(3m)
-
재정 규모
-
VWAP
-

AST 최신 뉴스

Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat...

BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech...

ALAMEDA, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment...

Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small C...

FREMONT, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer...

Asterias Biotherapeutics Reports Third Quarter Results

Clinical Programs Continue to ProgressRecent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating ExpensesRecently Announced Definitive Merger Agreement...

BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company

BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology Asterias Stockholders to Receive 0.71...

BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update

Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence...

Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018

FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat...

Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study

Meeting with Food and Drug Administration Remains on Track for End of 2018 FREMONT, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a...

Asterias Biotherapeutics Announces Facilities and IP License Option Agreements

FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat...

FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Cli...

FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

AST - Frequently Asked Questions (FAQ)

What is the current Asterias Biotherapeutics, Inc. share price?
The current share price of Asterias Biotherapeutics, Inc. is US$ 0.945
What is the 1 year trading range for Asterias Biotherapeutics, Inc. share price?
Asterias Biotherapeutics, Inc. has traded in the range of US$ 0.00 to US$ 0.00 during the past year

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
CHROChannel Therapeutics Corporation
US$ 1.90
(97.92%)
14.26M
GPUSHyperscale Data Inc
US$ 4.60
(22.99%)
215.83k
VINEFresh Vine Wine Inc
US$ 0.6899
(22.98%)
376.38k
RHERegional Health Properties Inc
US$ 2.40
(18.81%)
225.06k
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 13.245
(16.80%)
62.42M
FOXOFOXO Technologies Inc
US$ 0.2295
(-27.14%)
11.33M
OSTXOS Therapies Incorporated
US$ 3.03
(-26.46%)
1.63M
AEONAEON Biopharma Inc
US$ 0.1401
(-18.02%)
29.85M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
US$ 12.56
(-16.32%)
26.3M
BOILProShares Ultra Bloomberg Natural Gas New
US$ 67.43
(-14.52%)
3.87M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 32.49
(8.34%)
69.67M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 13.245
(16.80%)
62.42M
FXIiShares China Large Cap
US$ 30.40
(1.91%)
59.69M
SPYSPDR S&P 500
US$ 597.58
(1.00%)
57.16M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 18.33
(-8.03%)
53.83M
stockprofitter stockprofitter 5 분 전
Because the boss said so winky wink wink
FNMA
GUNSMOKE GUNSMOKE 6 분 전
https://youtu.be/0DQup4hd1_o
UMAV
Shawonsarker84 Shawonsarker84 8 분 전
Thiago is President/CEO of Ybyra and building the new FinCapital/HUMBL. He's also been a partner of several other companies, but one stood out - JVS consulting. JVS is a consulting firm dealing in Oil and Gas 💡
https://x.com/WWTP_Consultant/status/1880452701844304066?t=GjDbTot-zSXyAib
HMBL
PEACHMAN PEACHMAN 8 분 전
SGP AG currently generating revenues


https://impactfusionbrands.com/product/supreme-ag/
IFUS
3331 3331 9 분 전
BIEL: 911 FINAL TRADE, NEWS PENDING, GOLDEN CROSS BREAKOUT!
3331 3331 10 분 전
BIEL: 911 FINAL TRADE, NEWS PENDING, GOLDEN CROSS BREAKOUT!
chen1992 chen1992 12 분 전
Dino, would a RS mean we’re screwed?
TGLO
findit findit 14 분 전
Very solid week. A 6 bag last 3 weeks. More to come?
STRH
88TH MAN 88TH MAN 14 분 전
Throughout January, planets Venus, Mars, Jupiter, Saturn, Neptune and Uranus will all be visible in the night sky. However, the best time to catch a glimpse of the planets will be on January 29, the night of the new moon when the sky will be clear. Therefore, January 29, will be "Planet Parade 202
FBEC
quicksniff quicksniff 15 분 전
3-1/2" is all he get. Fak him. 
NBRI
devil dog 96 devil dog 96 15 분 전
Jimmyboysham® 🤡 with his copy & paste no proof scam theory clown🤡 show promo propaganda. 😃 Why is it so important for you to get traders to sell the bottom of this micro float bottom play before management starts marketing her? 🤡

" Oh “Proof” needed aga
ATMH
NebraskaOTC NebraskaOTC 18 분 전
Negative. Quality has exposed $RDAR as a huge SCAM. He is batting 1000 on these!
RDAR
oilin07 oilin07 18 분 전
Are you ready?
BLLB
satter satter 19 분 전
Based on what I'm reading here..

RNVA owns FOXO

Does an EM get to own a NYSE stock and stay in EM?

If you or anybody have a positive or not, take on this..

I'm all ears..


Yes it's true based on what you read here, RNV
FOXO RNVA
Slaytanic420 Slaytanic420 21 분 전
Delusional hmbl pumpers on x stock twits and x
HMBL
eskayes eskayes 22 분 전
That is beautiful
TGLO
GUNSMOKE GUNSMOKE 23 분 전
https://youtu.be/P96KFQQSeoE
UMAV
Eli's Gone Eli's Gone 25 분 전
I remember when Conseco broke the $5M barrier---bunch of us guys were having a beer after work---we were all at or around $50K/yr...so we started BS'in about how the $5M would equate in our world...I said just take 2 zeroes off all your current stuff while keeping your current salary---a $100 dinner
Value_Investor Value_Investor 27 분 전
This Diamond-In-Rough is Super Undervalued now! This Hidden Gem is also at Hyper Oversold status!

Buying its OTC peer (FCCN) at today's high $9.9 = buying FRCN at $1.2881 which is 537 Times of its recent high $0.0024!

Buying FCCN at its Record high $41.3 = buy
FCCN FRCN
GUNSMOKE GUNSMOKE 29 분 전
UMAC !! BREAK THE FLAG GOIRGIE DREW FCUK-IT !!
UMAC
janice shell janice shell 30 분 전
Very nasty.
PickStocks PickStocks 31 분 전
Yes....this will be a monster
COOP

최근 히스토리

Delayed Upgrade Clock